Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resident Memory T Cells and Their Effect on Cancer.
Craig DJ, Creeden JF, Einloth KR, Gillman CE, Stanbery L, Hamouda D, Edelman G, Dworkin L, Nemunaitis JJ. Craig DJ, et al. Among authors: stanbery l. Vaccines (Basel). 2020 Oct 1;8(4):562. doi: 10.3390/vaccines8040562. Vaccines (Basel). 2020. PMID: 33019493 Free PMC article. Review.
Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology.
Ngo N, Choucair K, Creeden JF, Qaqish H, Bhavsar K, Murphy C, Lian K, Albrethsen MT, Stanbery L, Phinney RC, Brunicardi FC, Dworkin L, Nemunaitis J. Ngo N, et al. Among authors: stanbery l. Future Oncol. 2019 Nov;15(33):3861-3876. doi: 10.2217/fon-2019-0374. Epub 2019 Oct 31. Future Oncol. 2019. PMID: 31668087 Review.
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.
Willis O, Choucair K, Alloghbi A, Stanbery L, Mowat R, Charles Brunicardi F, Dworkin L, Nemunaitis J. Willis O, et al. Among authors: stanbery l. Cancer Gene Ther. 2020 Sep;27(9):634-644. doi: 10.1038/s41417-020-0164-0. Epub 2020 Jan 28. Cancer Gene Ther. 2020. PMID: 31988478 Review.
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Rocconi RP, et al. Among authors: stanbery l. Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7. Lancet Oncol. 2020. PMID: 33271095 Clinical Trial.
FDA efficiency for approval process of COVID-19 therapeutics.
Cassidy C, Dever D, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. Cassidy C, et al. Among authors: stanbery l. Infect Agent Cancer. 2020 Dec 1;15(1):73. doi: 10.1186/s13027-020-00338-z. Infect Agent Cancer. 2020. PMID: 33292374 Free PMC article. Review.
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.
Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, Bognar E, Stanbery L, Horvath S, Manley M, Nemunaitis J, Walter A, Rocconi RP. Oh J, et al. Among authors: stanbery l. Gynecol Oncol Rep. 2020 Sep 17;34:100648. doi: 10.1016/j.gore.2020.100648. eCollection 2020 Nov. Gynecol Oncol Rep. 2020. PMID: 33364285 Free PMC article. No abstract available.
43 results